Delcath Systems, Inc. (DCTH)
| Market Cap | 80.02M |
| Revenue (ttm) | 1.65M |
| Net Income (ttm) | -24.21M |
| Shares Out | 2.90M |
| EPS (ttm) | -8.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $12.80 |
| Previous Close | $12.67 |
| Change ($) | 0.13 |
| Change (%) | 1.03% |
| Day's Open | 12.70 |
| Day's Range | 12.36 - 12.89 |
| Day's Volume | 181,742 |
| 52-Week Range | 6.06 - 25.18 |
20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold 20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold
Shares of Delcath Systems (NASDAQ:DCTH) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were down 1400.00% over the past year to ($0.60), which beat the estima...
Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with...
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repor...
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announ...
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, annou...
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, ann...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today a...
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today a...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announce...
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announce...
Overall Response Rate of 72% observed in patients with metastases confined to the liver Overall Response Rate of 72% observed in patients with metastases confined to the liver
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective October 1, 2020...
Safety data of early part of FOCUS trial have been publicly disseminated.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today ...
Wall Street recommends to buy shares of SenesTech Inc (NASDAQ:SNES) and Delcath Systems Inc (NASDAQ:DCTH), even though these two stocks have disappointed so much over the prior 52 weeks through Monday, ...
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...
Delcath Systems, Inc. (DCTH) CEO John Purpura on Q2 2020 Results - Earnings Call Transcript
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today an...
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today ...
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the li...
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective respon... [Read more...]
| Industry Medical Devices | Founded 1988 |
| CEO Jennifer Simpson | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol DCTH |
Financial Performance
In 2020, DCTH's revenue was $1.65 million, an increase of 4.18% compared to the previous year's $1.58 million. Losses were -$24.16 million, 172.1% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is 22.75, which is an increase of 77.73% from the latest price.